Supernus Pharmaceuticals (SUPN) Amortizatization of Intangibles (2017 - 2026)
Supernus Pharmaceuticals (SUPN) reported Amortizatization of Intangibles of $192000.0 for Q1 2026, down 82.12% year-over-year from $1.1 million in Q1 2025, and down 96.77% quarter-over-quarter from $6.0 million in Q4 2025.
Supernus Pharmaceuticals (SUPN) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 10 years of Amortizatization of Intangibles data on file, last reported at $192000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $192000.0, down 82.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.1 million (down 15.7% YoY), and the FY2025 annual result was $8.0 million, up 46.37% from the prior year.
- Amortizatization of Intangibles retreated to $192000.0 in Q1 2026 per SUPN's latest filing, from $6.0 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $7.9 million in Q4 2024 and troughed at -$2.1 million in Q3 2022.
- A 5-year average of $618411.8 and a median of $32000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles plunged 3938.89% in 2023, then jumped 1193.4% in 2024.
- A 5-year view of Amortizatization of Intangibles shows it stood at -$18000.0 in 2022, then sank by 3938.89% to -$727000.0 in 2023, then jumped by 1193.4% to $7.9 million in 2024, then declined by 25.11% to $6.0 million in 2025, then sank by 96.77% to $192000.0 in 2026.
- Business Quant data shows SUPN's Amortizatization of Intangibles at $192000.0 in Q1 2026, $6.0 million in Q4 2025, and $921000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amort. of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.30 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 242,000.00 |
| 10 | Supernus Pharmaceuticals | 2.57 Bn | 2.19 Bn | - | 192,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 192,000.00 |
| Mar 31, 2026 | 192,000.00 |
| Dec 31, 2025 | 5.95 Mn |
| Dec 31, 2025 | 5.95 Mn |
| Sep 30, 2025 | 921,000.00 |
| Sep 30, 2025 | 921,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Mar 31, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | 7.95 Mn |
| Dec 31, 2024 | 7.95 Mn |
| Sep 30, 2024 | -966,000.00 |
| Sep 30, 2024 | -966,000.00 |
| Jun 30, 2024 | 363,000.00 |
| Jun 30, 2024 | 363,000.00 |
| Mar 31, 2024 | -1.89 Mn |
| Mar 31, 2024 | -1.89 Mn |
| Dec 31, 2023 | -727,000.00 |
| Dec 31, 2023 | -727,000.00 |